AUA 2025 non-invasive bladder cancer, efficacy of Bacillus Calmette Guérin (BCG) induction with maintenance to gemcitabine + docetaxel (Gem/Doce) maintenance.
AUA 2025 artificial intelligence-powered predictive biomarker, intravesical BCG versus gemcitabine + docetaxel in high-grade, non-muscle invasive bladder cancer (NMIBC) patients, EA-8212 (BRIDGE), computational histology artificial…
AUA 2025 disitamab vedotin combined with BCG for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC), HER2 expression.
AUA 2025 results of ENVISION, UGN-102, non-muscle invasive bladder cancer (NMIBC), ENVISION trial, urinary retention, urethral stenosis.
AUA 2025 cost-effectiveness analysis of 89Zr-girentuximab PET-CT (TLX250) to guide management of small renal masses,
AUA 2025 prostate cancer clinical trials in the VA, veterans with prostate cancer, VA healthcare system.
AUA 2025, non–muscle-invasive bladder cancer (NMIBC), TAR-200 monotherapy, SunRISe-1 trial, BCG-unresponsive disease.
AUA 2025 BOND-003 Cohort C, Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ.
AUA 2025 Focal Therapy in Prostate Cancer, ProtecT study, Phase II focal therapy trial,
AUA 2025, non muscle invasive bladder cancer (NMIBC), BCG Unresponsive NMIBC, nadofaragene, KEYNOTE-057 study, gemcitabine-docetaxel.
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
